Dosing and uses of Plecanatide
Chronic Idiopathic Constipation
Pending FDA approval for chronic idiopathic constipation
Pharmacology of Plecanatide
Mechanism of action
Uroguanylin analog, guanylate cyclase C (GC-C) agonist; activation of GC-C located on the luminal surface of intestinal epithelial cells leads to increased cyclic guanosine monophosphate (cGMP), anion secretion, fluid secretion, and intestinal transit
Appears to work within the intestine, rather than systemically; elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit
